

Specialty Medication Prior Authorization Cover Sheet

(This cover sheet should be submitted along with a Pharmacy Prior Authorization Medication Fax Request Form. Please refer to <u>www.uhcprovider.com</u> for medication fax request forms.)

Patient Information							
Patient's Name:							
Insurance ID:	Date of Birth:	Height:	Weight:				
Address:		Apartment #:					
_City:	State:	Zip Code:					
Phone Number:	Alternate Phone:	Sex: 🗌 Male	Female				
Provider Information							
Provider's Name:	Provider ID Number:						
Address:	City:	State: Zip C	ode:				
Suite Number:	Building Number:						
Phone Number:	Fax number:						
Provider's Specialty:							
Medication Information							
Medication:	Quantity:	ICD10 Code:					
Directions:	Diagnosis:	Refills:					
Physician Signature**:		Initial here if DAW	1:				
Physician Signature**: By signing above, the physician is providing the specialty pharmacy with a prescription that can be used to facilitate the dispensing and/or coordination of delivery for the requested medication.							
Medication Instructions							
Has the patient been instructed on how to Self	-Administer?	🗌 Yes 🗌 No					
Is this medication a New Start?		🗌 Yes 🗌 No					
If continuation please provide the following:	Initiation Date: / /	Date of Last Dos	e: / /				
ls there documentation of positive clinical re	sponse to current therapy?	🗆 Yes 🗆 No					
**Please attach any pertinent clinical information that would pertain to support stated diagnosis. Additional clinical information may be needed depending on your patients plan, including medication(s) previously tried and failed.							
Delivery Instructions							
Note: Delivery coordination requires a "Physic "Provider Information" and "Patient In Note: All necessary ancillary supplies are prov	formation"		very				
Ship to: Physician's Office 🗌 Patient's Add	dress 🗌 Date medication is r	needed: / /					
Medication Administered: Home Health							
	Self-Administered 🗌 LTC 🗌	Physician's Offic	e 🗌				

this facsimile is intended to be for the sole use of the individual(s) or entity named above. If you are not the intended recipient, be aware that any disclosure, copying, distribution or use of the contents of this information is strictly prohibited by law and will be vigorously prosecuted. If you have received this electronic fax transmission in error, please notify the sender immediately and destroy all electronic hard copies of the communications including attachments Specialty Med Fax Cover Letter_C&S_9.11



Tafinlar - Washington

Plan

PRIOR AUTHORIZATION REQUEST FORM

Please complete this entire form and fax it to: 866-940-7328. If you have questions, please call 800-310-6826. This form contains multiple pages. Please complete all pages to avoid a delay in our decision. Allow at least 24 hours for review.

Section A – Member Information	n							
First Name:	Last Na	Last Name:			Member ID:			
Address:								
City:	State:	State:			ZIP Code:			
Phone:	DOB:	DOB:		Allergies:				
Primary Insurance Information:								
Is the requested medication New or Continuation of Therapy? If continuation, list start date:								
Is this patient currently hospital		No If recently discha	arged, list discha	arge date:				
Section B - Provider Information	n	Last Name:			M.D./D.O.			
Address:		City:		State:	ZIP code:			
Phone: Fax:	,	NPI#:		Specialty:				
Office Contact Name / Fax attention				opeolaity.				
Section C - Medical Information								
Medication:				Strength:				
Directions for use:				Quantity:				
Diagnosis (Please be specific & provide as much information as possible):					ICD-10 CODE:			
Is this member pregnant? Yes No If yes, what is this member's due date?								
)))		es, what is this men	nber's due date?					
Section D – Previous Medication	n Trials				con for failure /			
)))		es, what is this men Directions	nber's due date? Dates of Thei	rapy Rea	son for failure /			
Section D – Previous Medication	n Trials			rapy Rea				
Section D – Previous Medication	n Trials			rapy Rea				
Section D – Previous Medication	n Trials			rapy Rea				
Section D – Previous Medication	n Trials			rapy Rea				
Section D – Previous Medication Medications Section E – Additional information	n Trials Strength	Directions	Dates of Thei	rapy Rea dis	scontinuation			
Section D – Previous Medication Medications Section E – Additional information	n Trials Strength	Directions	Dates of Thei	rapy Rea dis	scontinuation			
Section D – Previous Medication Medications Section E – Additional information	n Trials Strength	Directions	Dates of Thei	rapy Rea dis	scontinuation			
Section D – Previous Medication Medications Section E – Additional information	n Trials Strength	Directions	Dates of Thei	rapy Rea dis	scontinuation			
Section D – Previous Medication Medications Section E – Additional information	n Trials Strength	Directions	Dates of Thei	rapy Rea dis	scontinuation			
Section D – Previous Medication Medications Section E – Additional information	n Trials Strength	Directions	Dates of Thei	rapy Rea dis	scontinuation			
Section D – Previous Medication Medications Section E – Additional information	n Trials Strength	Directions	Dates of Thei	rapy Rea dis	scontinuation			
Section D – Previous Medication Medications Section E – Additional information	n Trials Strength	Directions	Dates of Thei	rapy Rea dis	scontinuation			
Section D – Previous Medication Medications Section E – Additional information	n Trials Strength	Directions	Dates of Thei	rapy Rea dis	scontinuation			

Tafinlar - Washington PRIOR AUTHORIZATION REQUEST FORM

UnitedHealthcare

Community Plan

Member Fir	st name:	Member Last name:		Member DOB:		
	Clinical and Drug Specific Information					
ALL REQUESTS						
□ Yes □ No	Does the patient have on Unresectable Melanoma Metastatic Melanoma Metastatic Brain Lesions Central Nervous System		 Melanoma inv Non-Small Cel Anaplastic Thy 	applies) olving the lymph nodes Il Lung Cancer (NSCLC) vroid Cancer (ATC) thle cell, or papillary carcinoma		
🗆 Yes 🗆 No	□ Yes □ No Is the medication being requested for a use supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium?					
🗆 Yes 🗆 No	Does the patient have on BRAF V600	BRAF V600E		heck which applies)		
		MELANO				
□ Yes □ No	Is this prescribed as adju			with Mekinist (trametinib)?		
		NON-SMALL CELL L				
□ Yes □ No	Is the disease one of the following: (If yes, check which applies)					
□ Yes □ No	Tafinlar will be used as a single agent if the combination of Mekinist and Tafinlar is not tolerated					
		ANAPLASTIC THYROID				
□ Yes □ No	Will Tafinlar be used in c		· · · ·			
□ Yes □ No	Is the disease one of the following: (If yes, check which applies) Metastatic Locally advanced Unresectable 					
🗆 Yes 🗆 No	No Is Tafinlar prescribed as adjuvant therapy following resection?					
CENTRAL NERVOUS SYSTEM (CNS) CANCERS						
🗆 Yes 🗆 No	Io Does the patient have metastatic brain lesions?					
🗆 Yes 🗆 No	Is Tafinlar active against the primary tumor (melanoma)?					
🗆 Yes 🗆 No	Will Tafinlar be used in c	ombination with Mekini	st (trametinib)?			
FOLLICULAR/HURTHE CELL/PAPILLARY CARCINOMA						
🗆 Yes 🗆 No	Is the disease one of the following: (If yes, check which applies) Unresectable locoregional recurrent Persistent Metastatic 					
🗆 Yes 🗆 No	Does the patient have one of the following disease types: □ Symptomatic □ Progressive					
🗆 Yes 🗆 No	Is the disease refractory to radioactive iodine treatment?					
CONTINUATION OF THERAPY						
□ Yes □ No	Does the patient show ev	idence of progressive of	disease while or	n Tafinlar therapy?		
□ Yes □ No Does the patient have a documented positive clinical response to Tafinlar therapy?						

Physician Signature: _____

Date:

Confidentiality Notice: This transmission contains confidential information belonging to the sender and United Healthcare. This information is intended only for the use of UnitedHealthcare. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action involving the contents of this document is prohibited. If you have received this telecopy in error, please notify the sender immediately.